Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Calgary

$105,000.00

Development of a therapeutic single domain antibody to target the hepatitis B virus covalently closed circular DNA genome

FY 2022-23

Summary
Despite the availability of an effective vaccine, over 296 million people worldwide and 250,000 Canadians are chronically infected with the hepatitis B virus (HBV). The HBV specifically targets liver cells and can cause a persistent infection that can lead to cirrhosis (severe liver scarring), hepatocellular carcinoma (primary liver cancer), and liver failure. HBV related liver complications accounts for over 880,000 deaths annually. The ability of HBV to cause chronic infection is due, in part, to its highly stable covalently closed circular DNA genome (called cccDNA), which enters and remains in the nucleus of infected liver cells following viral infection. Once in the nucleus, the cccDNA acts as a "mini-factory" to produces new virus particles. There is no cure for chronic HBV infection, and current first line anti-HBV treatments block the virus at later steps, but do not directly affect the formation or destruction of cccDNA. To achieve a cure, the cccDNA needs to be targeted for elimination. With funding from this scholarship, I aim to (1) design a single domain antibody (sdAb) to directly target the HBV cccDNA genome; (2) characterize the effect of the sdAb on cccDNA stability and viral replication. Our lab has demonstrated previously that there is a region on the HBV cccDNA genome that plays a critical role in HBV replication initiation and has a highly conserved sequence and structure. To complete these aims, we have designed a sdAb to specifically bind to this key conserved region on the HBV cccDNA minigenome. The sdAb will be tested in HBV infected liver cells for drug toxicity, efficacy, and markers of HBV replication. To study the sdAbs ability to target HBV infected liver cells, the sdAb will be labelled with a marker that can be visualized. With this research I will provide insight into new cccDNA targeting approaches which will inform development of an HBV cure to improve health outcomes of chronically HBV infected patients.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
475928
Name
D'souza Simmone
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of a therapeutic single domain antibody to target the hepatitis B virus covalently closed circular DNA genome
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antiviral Drug Development; Hepatitis B Virus; Virology
Abstract
Despite the availability of an effective vaccine, over 296 million people worldwide and 250,000 Canadians are chronically infected with the hepatitis B virus (HBV). The HBV specifically targets liver cells and can cause a persistent infection that can lead to cirrhosis (severe liver scarring), hepatocellular carcinoma (primary liver cancer), and liver failure. HBV related liver complications accounts for over 880,000 deaths annually. The ability of HBV to cause chronic infection is due, in part, to its highly stable covalently closed circular DNA genome (called cccDNA), which enters and remains in the nucleus of infected liver cells following viral infection. Once in the nucleus, the cccDNA acts as a "mini-factory" to produces new virus particles. There is no cure for chronic HBV infection, and current first line anti-HBV treatments block the virus at later steps, but do not directly affect the formation or destruction of cccDNA. To achieve a cure, the cccDNA needs to be targeted for elimination. With funding from this scholarship, I aim to (1) design a single domain antibody (sdAb) to directly target the HBV cccDNA genome; (2) characterize the effect of the sdAb on cccDNA stability and viral replication. Our lab has demonstrated previously that there is a region on the HBV cccDNA genome that plays a critical role in HBV replication initiation and has a highly conserved sequence and structure. To complete these aims, we have designed a sdAb to specifically bind to this key conserved region on the HBV cccDNA minigenome. The sdAb will be tested in HBV infected liver cells for drug toxicity, efficacy, and markers of HBV replication. To study the sdAbs ability to target HBV infected liver cells, the sdAb will be labelled with a marker that can be visualized. With this research I will provide insight into new cccDNA targeting approaches which will inform development of an HBV cure to improve health outcomes of chronically HBV infected patients.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
D'souza, Simmone
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~